137 related articles for article (PubMed ID: 37698736)
1. N
Wang Y; Jin P; Wang X
Apoptosis; 2024 Feb; 29(1-2):142-153. PubMed ID: 37698736
[TBL] [Abstract][Full Text] [Related]
2. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour immunity controlled through mRNA m
Han D; Liu J; Chen C; Dong L; Liu Y; Chang R; Huang X; Liu Y; Wang J; Dougherty U; Bissonnette MB; Shen B; Weichselbaum RR; Xu MM; He C
Nature; 2019 Feb; 566(7743):270-274. PubMed ID: 30728504
[TBL] [Abstract][Full Text] [Related]
5. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
[TBL] [Abstract][Full Text] [Related]
6. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer.
Yu Y; Huang X; Liang C; Zhang P
Eur J Pharmacol; 2023 Oct; 957():176007. PubMed ID: 37611839
[TBL] [Abstract][Full Text] [Related]
7. N
Tang B; Bi L; Xu Y; Cao L; Li X
Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37817028
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
9. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
[TBL] [Abstract][Full Text] [Related]
10. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
11. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner.
Li P; Shi Y; Gao D; Xu H; Zou Y; Wang Z; Li W
Int J Biol Sci; 2022; 18(16):6145-6162. PubMed ID: 36439881
[No Abstract] [Full Text] [Related]
12. Methionine deficiency facilitates antitumour immunity by altering m
Li T; Tan YT; Chen YX; Zheng XJ; Wang W; Liao K; Mo HY; Lin J; Yang W; Piao HL; Xu RH; Ju HQ
Gut; 2023 Mar; 72(3):501-511. PubMed ID: 35803704
[TBL] [Abstract][Full Text] [Related]
13. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
Wang H; Tang A; Cui Y; Gong H; Li H
Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
[TBL] [Abstract][Full Text] [Related]
14. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
15. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
[TBL] [Abstract][Full Text] [Related]
16. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
17. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
[TBL] [Abstract][Full Text] [Related]
18. The m
Diao H; Tan H; Hu Y; Wang R; Cai P; Huang B; Shao X; Yan M; Yin C; Zhang Y
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259333
[TBL] [Abstract][Full Text] [Related]
19. Targeting m
Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
[TBL] [Abstract][Full Text] [Related]
20. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
